• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / Anakinra (Kineret) is Safe and Well Tolerated in RA Patients with Comorbid Conditions from Johns Hopkins Arthritis

Anakinra (Kineret) is Safe and Well Tolerated in RA Patients with Comorbid Conditions from Johns Hopkins Arthritis

April 13, 2005 By Arthritis Center


Anakinra™(Kineret) is safe and well tolerated in RA patients with Comorbid Conditions

AnakinraTM (Kineret) is an interleukin-1 receptor antagonist approved for treatment in patients with rheumatoid arthritis (RA). In this study, Fleischmann et al (Arthritis Rheum 48:927, 2003) evaluated the safety and efficacy of anakinra in patients with and without comorbid conditions and in combination with conventional DMARDs. The preliminary results of this study have been summarized previously in our 2002 Eular Highlights where further details can be found.

Methods: In a large, randomized, placebo-controlled trial, the safety of anakinra was evaluated in 1,399 patients with RA. Patients were randomly assigned to receive daily subcutaneous injections of either 100 mg of anakinra or placebo. Patients were allowed to continue their disease-modifying antirheumatic drugs (DMARDs) except for anti-TNF agents which were discontinued. The anakinra- and placebo-treated groups were similar in terms of arthritis activity, comorbid conditions (asthma, COPD, , and concomitant medications/DMARDs.

Results: These data represent the first six months of the study. Serious adverse events occurred at a similar rate in the anakinra and placebo groups (7.7% and 7.8 %, respectively). The rate of all infectious events was 41.2% (460 of 1116) in patients treated with anakinra and 43.5% (123 of 283) in patients treated with placebo. There was a trend towards more serious infections in the anakinra group (n=23, 2.1%) compared to the placebo group (n=1, 0.4%), although this difference was not statistically significant (p=0.068). These infections were primarily pneumonias and cellulitis. There were no cases of reactivated tuberculosis or other opportunistic infections. An analysis of potential risk factors (e.g., specific comorbid conditions, duration of RA, concomitant medications, etc.) for these infections was conducted. None were significantly associated with increased risk for infection, although there was a trend towards more infections in patients with asthma.

Conclusions: Anakinra is safe and well tolerated in a diverse population of patients with RA, including those with comorbid conditions and those receiving single and multiple background DMARDs.

Editorial Comment: Anakinra (as monotherapy) has proven to be safer than the TNF antagonists in terms of opportunistic infections. Anakinra is a relatively weak and short-lived inhibitor of IL-1. It will be interesting to see the risk of infections if and when more potent IL-1 inhibitors are developed (e.g., IL-1 trap). It is also useful to remember that when anakinra and etanercept were combined in a preliminary open-label trial, there was a high rate of non-opportunistic infections. This combination should be avoided (as it was in the above study).

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy